Continuous subcutaneous insulin infusion: Short-term benefits apparent, long-term benefits speculative

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 2, 2004, Pages 104-108

  Hammond, Peter ^a  

^a HARROGATE DISTRICT HOSPITAL   (United Kingdom)

Author keywords

Continuous subcutaneous insulin infusion (CSII); Glycaemic control; Hypoglycaemia; Macrovascular complications; Microvascular complications; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ANTIBIOTIC AGENT; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC KETOACIDOSIS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE MARKER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION SITE INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN INFUSION; INSULIN PUMP; INSULIN SENSITIVITY; LONG TERM CARE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT;

EID: 2442507820     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040020701     Document Type: Article

References (44)

1. Diabetes Control and Complications Trial Research Group: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-76.
2. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983;24:326-9.
3. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:1-6.
4. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin Pump Therapy: A meta-analysis. Diabetes Care 2003;26:1079-87.
5. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000;23:1232-5.
6. Melki V, Renard E, Lassmann-Vague V etal. Improvement of HbA1c and blood glucose stability in IDDM patients with lispro insulin analogue in external pumps. Diabetes Care 1998;21:977-81.
7. Renner P, Pfützner A, Trautman M, Harzer O, Sauter K, Landraf R. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.
8. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.
9. Bode B, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy with type 1 diabetes. Diabetes Care 2001;24:69-72.
10. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996;19:324-7.
11. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diab Res Clin Pract 1995; 27:199-204.
12. Dudley S, Hammond PJ. Safety aspects of continuous subcutaneous insulin infusion (CSII). Diabet Med 2002:19(suppl 2):A50.
13. Bruttomesso D, Pianta A, Crazzolara D et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002;19:628-34.
14. Linkeschova R, Raoul M, Bott U, Berger M, Spaul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002;19:746-51.
15. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycaemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-84.
16. De Vries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor control. Diabetes Care 2002;25:2074-80.
17. DCCT. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874-86.
18. The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA 1988;260:36-41.
19. Olsen T, Richelsen B, Ehlers N, Beck-Nielsen H. Diabetic retinopathy after 3 years treatment with continuous subcutaneous insulin infusion. Arch Ophthalmol Copenh 1987;65:185-9.
20. Helve E, Laatikainen L, Merenmies L, Koivisto VA. Continuous insulin infusion therapy and retinopathy in patients with type 1 diabetes. Acta Endocrinol Copenh 1987;115:313-19.
21. Bending JJ, Viberti GC, Bilous RW, Keen H. Eight-month correction of hyperglycemia in insulin-dependent diabetes mellitus is associated with a significant and sustained reduction of urinary albumin excretion rates in patients with microalbuminuria. Diabetes 1985;34:69-73.
22. Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 1984;7:331-7.
23. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986;2:1300-04.
24. Beck-Nielsen H, Olesen T, Mogensen CE et al. Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. Diabetes Res 1990;15:185-90.
25. Chantelau E, Wichmann P. Pathological proteinuria in patients with insulin-dependent diabetes mellitus: relation to intensive insulin therapy. Exp Clin Endocrinol 1992;99:164-8.
26. Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. Acta Endocrinol Copenh 1988;117:19-25.
27. Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabet Complications 1987;1:91-5.
28. Beck-Nielsen H, Richelsen B, Mogensen CE et al. Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 1985;8:585-9.
29. Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994;37:483-90.
30. Daubresse JC, Henrivaux P, Bailly A, Lemy C, Duchateau A. Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. Diabete Metab 1983;9:45-52.
31. Bertelsmann FW, Heimans JJ, Van Rooy JC, Dankmeijer HF, Visser SL, Van der Veen EA. Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion. J Neuro Neurosurg Psych 1987;50:1337-41.
32. Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982;5:386-90.
33. Kronert K, Hulser J, Luft D, Stetter T, Eggstein M. Effects of continuous subcutaneous insulin infusion and intensified conventional therapy on peripheral and autonomic nerve dysfunction. J Clin End Metab 1987;64:1219-23.
34. Fedele D, Bellavere F, Cardone C, Ferri M, Crepaldi G. Improvement of cardiovascular autonomic reflexes after amelioration of metabolic control in insulin-dependent diabetes subjects with severe autonomic neuropathy. Horm Metab Res 1985;17:410-13.
35. Lawson P, Trayner I, Rosenstock J et al. The effect of continuous subcutaneous insulin infusion on serum lipids. Diabetes Met 1984;10:239-44.
36. Lormeau B, Aurousseau MH, Valensi P, Paries J, Attali JR. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism 1997;46:1074-9.
37. Turk Z, Flego I, Kerum G. Platelet aggregation in type 1 diabetes without microvascular disease during continuous subcutaneous insulin infusion. Horm Metab Res 1996;28:95-100.
38. Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley C, Ward JD. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 1991;14:738-44.
39. Raskin P, Bode BW, Marks JB et al. Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes. Diabetes Care 2003;26:2598-603.
40. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-6.
41. Della Casa L, del Rio G, Glaser B, Cerasi E. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. Am J Med 1991;90:37S-45S.
42. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol Copenh 1988;118:365-73.
43. Valensi P, Moura I, Le Magoarou M, Paries J, Perret G, Attali JR. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabetes Metab 1997;23:51-7.
44. Pouwels MJ, Tack CJ, Hermus AR, Lutterman JA. Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients. Diabet Med 2003;20:76-9.